Mabwell Biotech is a Chinese innovative biopharmaceutical company.
Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 29, 2020 | Series A | $278.50M | 9 | Shiyu Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Shiyu Capital | Yes | Series A |
Haitong Leading Capital Management | — | Series A |
Founder H Fund | — | Series A |
Huajin Capital | — | Series A |
Huarong Rongde Asset Management | — | Series A |
Loyal Valley Capital | — | Series A |
Oriental Fortune Capital | — | Series A |
Sincere Capital | — | Series A |
Winfast Holding | — | Series A |